Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of obexelimab in relapsing multiple sclerosis
2024-512707-40-00Phase 2Authorised
- Sponsor
- Zenas BioPharma
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Obexelimab with Placebo (2 arms). Primary endpoint: Cumulative number of new gadolinium-enhancing T1 hyperintense lesions over Week 8 and Week 12. Planned start Nov 2024; status: authorised.
02
Drugs
obexelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-512707-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512707-40-00.